Stratrix
On the Record · BioNTech

BioNTech acquisitions, on the record

The businesses BioNTech bought and sold, as its annual reports describe them, with the cash it reported paying for acquisitions each year and every deal filing since 2016.

Deals its annual reports describe

BusinessDealWhenValue
InstaDeep Ltd.
Word for word“The total consideration to acquire the remaining InstaDeep shares, excluding the shares already owned by BioNTech, amounts to approximately €500 million in cash, BioNTech shares, and performance-based future milestone payments.” 20-F for 2023
acquisition—approximately €500 million in cash, BioNTech shares, and performance-based future milestone payments
Marburg manufacturing site (from Novartis)
Word for word“Our Marburg manufacturing facility was acquired from Novartis in 2020 for less than a hundred million euros and comprises eight large and small molecule production suites across more than 100,000 square feet.” 20-F for 2023
acquisition—less than a hundred million euros
Gaithersburg Clinical Manufacturing Facility (from Kite Pharma, Inc.)
Word for word“We acquired our site in Gaithersburg, Maryland from Kite Pharma, Inc. in August 2021.” 20-F for 2023
acquisitionAugust 2021—
Neon
Word for word“Our acquisition of Neon included technologies for using peripheral blood mononuclear cells, or PBMCs, (e.g., collected from apheresis material of patients) as a starting material to induce and/or expand ex vivo functional T cells specific for therapeutically-relevant neoantigens.” 20-F for 2023
acquisition——
MabVax Therapeutics Holding, Inc.
Word for word“We own patent assets acquired from MabVax Therapeutics Holding, Inc., or the MabVax Filings, that relate to various antibodies, including certain antibodies targeting sialyl Lewis A and ganglioside GD2, as well as nucleic acid encoding them.” 20-F for 2023
acquisition——
new subsidiary in Vienna, Austria
Word for word“In addition €127.5 million was attributable to the purchase of property, plant and equipment including the amounts spent with respect to our acquired facility in Gaithersburg, Maryland, United States as well as €20.8 million spent upon the acquisition of our new subsidiary in Vienna, Austria.” 20-F for 2023
acquisition—€20.8 million
Biotheus, Inc.
Word for word“Following the satisfaction of several customary closing conditions and regulatory approvals as defined in the Merger Agreement, the acquisition closed on January 31, 2025.” 20-F for 2024
acquisitionJanuary 31, 2025—
Marburg manufacturing facility acquired from Novartis
Word for word“Our Marburg manufacturing facility was acquired from Novartis in 2020 for less than a hundred million euros and comprises eight large and small molecule production suites across more than 100,000 square feet.” 20-F for 2024
acquisition2020less than a hundred million euros
Gaithersburg R&D and GMP manufacturing site acquired from Kite Pharma, Inc.
Word for word“We acquired our site in Gaithersburg, Maryland from Kite Pharma, Inc., a Gilead Sciences company, in August 2021.” 20-F for 2024
acquisitionAugust 2021—
GMP-certified manufacturing facility in Singapore from Novartis Singapore Pharmaceutical Manufacturing Pte. Ltd.
Word for word“Ltd., entered into an agreement with Novartis Singapore Pharmaceutical Manufacturing Pte. Ltd. to acquire one of its GMP-certified manufacturing facilities.” 20-F for 2024
agreed acquisition——
Neon Therapeutics
Word for word“Many of the Neoantigen Filings are solely owned by BioNTech, or jointly owned by BioNTech and TRON; our acquisition of Neon added various Neoantigen Filings, including both BioNTech U.S.-owned and in-licensed filings.” 20-F for 2024
acquisition——
CureVac N.V.
Word for word“On December 15, 2025, we completed our acquisition of CureVac.” 20-F for 2025
acquisitionDecember 15, 2025—

Read from BioNTech’s annual reports (20-F for 2025, 20-F for 2024, 20-F for 2023) and the financial data it files with the SEC, as of 2026-03-10. Every quotation is word for word from the filing linked beside it; how these pages are built and checked. The full record is in its company data sheet.